273 related articles for article (PubMed ID: 29125918)
1. In Vitro Characterization of the eFlow Closed System Nebulizer with Glycopyrrolate Inhalation Solution.
Pham S; Ferguson GT; Kerwin E; Goodin T; Wheeler A; Bauer A
J Aerosol Med Pulm Drug Deliv; 2018 Jun; 31(3):162-169. PubMed ID: 29125918
[TBL] [Abstract][Full Text] [Related]
2. Satisfaction with the Use of eFlow Closed-System Nebulizer in Patients with Moderate-to-Very Severe Chronic Obstructive Pulmonary Disease: Findings from a Long-Term Safety Study.
Kerwin EM; Donohue JF; Ferguson GT; Ganapathy V; Ozol-Godfrey A; Rajagopalan K
J Aerosol Med Pulm Drug Deliv; 2019 Feb; 32(1):24-33. PubMed ID: 30457433
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of glycopyrrolate/eFlow
Kerwin E; Donohue JF; Goodin T; Tosiello R; Wheeler A; Ferguson GT
Respir Med; 2017 Nov; 132():238-250. PubMed ID: 28838685
[TBL] [Abstract][Full Text] [Related]
4. Long-term safety of glycopyrrolate/eFlow
Ferguson GT; Goodin T; Tosiello R; Wheeler A; Kerwin E
Respir Med; 2017 Nov; 132():251-260. PubMed ID: 28919143
[TBL] [Abstract][Full Text] [Related]
5. Glycopyrrolate/eFlow CS: The First Nebulized Long-Acting Muscarinic Antagonist Approved to Treat Chronic Obstructive Pulmonary Disease.
Pleasants RA
Ann Pharmacother; 2019 Mar; 53(3):285-293. PubMed ID: 30175596
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of systemic absorption and bronchodilator effect of glycopyrronium bromide delivered by nebulizer or a dry powder inhaler in subjects with chronic obstructive pulmonary disease.
Leaker BR; Singh D; Nicholson GC; Hezelova B; Goodin T; Ozol-Godfrey A; Galluppi G; Barnes PJ
Respir Res; 2019 Jun; 20(1):132. PubMed ID: 31253162
[TBL] [Abstract][Full Text] [Related]
7. Dose selection for glycopyrrolate/eFlow
Donohue JF; Goodin T; Tosiello R; Wheeler A
Respir Res; 2017 Dec; 18(1):202. PubMed ID: 29202767
[TBL] [Abstract][Full Text] [Related]
8. An overview of glycopyrrolate/eFlow® CS in COPD.
Kerwin E; Ferguson GT
Expert Rev Respir Med; 2018 Jun; 12(6):447-459. PubMed ID: 29774778
[TBL] [Abstract][Full Text] [Related]
9. In Vitro Effect of Different Airflow Rates on the Aerosol Properties of Nebulized Glycopyrrolate in the eFlow® Closed System and Tiotropium Delivered in the HandiHaler®.
Ohar JA; Bauer A; Sharma S; Sanjar S
Pulm Ther; 2020 Dec; 6(2):289-301. PubMed ID: 32809156
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of nebulized glycopyrrolate for administration using a high efficiency nebulizer in patients with chronic obstructive pulmonary disease.
Leaker BR; Barnes PJ; Jones CR; Tutuncu A; Singh D
Br J Clin Pharmacol; 2015 Mar; 79(3):492-500. PubMed ID: 25243340
[TBL] [Abstract][Full Text] [Related]
11. Role of nebulized glycopyrrolate in the treatment of chronic obstructive pulmonary disease.
Santus P; Radovanovic D; Cristiano A; Valenti V; Rizzi M
Drug Des Devel Ther; 2017; 11():3257-3271. PubMed ID: 29180850
[TBL] [Abstract][Full Text] [Related]
12. Health-Related Quality of Life Improvements in Moderate to Very Severe Chronic Obstructive Pulmonary Disease Patients on Nebulized Glycopyrrolate: Evidence from the GOLDEN Studies.
Ferguson GT; Kerwin EM; Donohue JF; Ganapathy V; Tosiello RL; Bollu VK; Rajagopalan K
Chronic Obstr Pulm Dis; 2018 Jun; 5(3):193-207. PubMed ID: 30584583
[No Abstract] [Full Text] [Related]
13. From bench to bedside: in vitro and in vivo evaluation of a neonate-focused nebulized surfactant delivery strategy.
Bianco F; Ricci F; Catozzi C; Murgia X; Schlun M; Bucholski A; Hetzer U; Bonelli S; Lombardini M; Pasini E; Nutini M; Pertile M; Minocchieri S; Simonato M; Rosa B; Pieraccini G; Moneti G; Lorenzini L; Catinella S; Villetti G; Civelli M; Pioselli B; Cogo P; Carnielli V; Dani C; Salomone F
Respir Res; 2019 Jul; 20(1):134. PubMed ID: 31266508
[TBL] [Abstract][Full Text] [Related]
14. Observational Real-World Study to Assess Clinical Characteristics and Device Satisfaction in Patients with COPD Treated with Glycopyrrolate/eFlow
Stephenson JJ; Dembek C; Caldwell-Tarr A; Conto RM; Paullin M; Kerwin EM
Int J Chron Obstruct Pulmon Dis; 2020; 15():1713-1727. PubMed ID: 32764916
[TBL] [Abstract][Full Text] [Related]
15. Robustness of aerosol delivery of amikacin liposome inhalation suspension using the eFlow® Technology.
Li Z; Perkins W; Cipolla D
Eur J Pharm Biopharm; 2021 Sep; 166():10-18. PubMed ID: 34082122
[TBL] [Abstract][Full Text] [Related]
16. Changes in performance of the Pari eFlow rapid and Pari LC Plus during 6 months use by CF patients.
Rottier BL; van Erp CJ; Sluyter TS; Heijerman HG; Frijlink HW; Boer AH
J Aerosol Med Pulm Drug Deliv; 2009 Sep; 22(3):263-9. PubMed ID: 19466906
[TBL] [Abstract][Full Text] [Related]
17. Nebulization of active pharmaceutical ingredients with the eFlow(®) rapid: impact of formulation variables on aerodynamic characteristics.
Beck-Broichsitter M; Prüfer N; Oesterheld N; Seeger W; Schmehl T
J Pharm Sci; 2014 Aug; 103(8):2585-9. PubMed ID: 24986144
[TBL] [Abstract][Full Text] [Related]
18. Aerosol Production by Vibrating Membrane Technology: Analysis of the Electrolyte Effect on Generated Droplet Size and Nebulizer Output Rate.
Beck-Broichsitter M
J Pharm Sci; 2017 Aug; 106(8):2168-2172. PubMed ID: 28479359
[TBL] [Abstract][Full Text] [Related]
19. A comparison of amount and speed of deposition between the PARI LC STAR® jet nebulizer and an investigational eFlow® nebulizer.
Coates AL; Green M; Leung K; Chan J; Ribeiro N; Ratjen F; Charron M
J Aerosol Med Pulm Drug Deliv; 2011 Jun; 24(3):157-63. PubMed ID: 21361784
[TBL] [Abstract][Full Text] [Related]
20. Effective nebulization of interferon-γ using a novel vibrating mesh.
Sweeney L; McCloskey AP; Higgins G; Ramsey JM; Cryan SA; MacLoughlin R
Respir Res; 2019 Apr; 20(1):66. PubMed ID: 30943978
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
